# Taxpas: Epidemiological and Survival Data in Breast Cancer Patients Treated with a Docetaxel-Based Chemotherapy Regimen in South Africa

Authors: Shun Devan Moodley; Alicia McMaster; Rashem Mothilal
Journal: Journal of Cancer Research
 (2013)

---

## Abstract

Breast cancer is the leading cancer among South African women. There is limited South African epidemiological data on triple-negative breast cancer (TNBC). Taxpas was a nonrandomized observational survey conducted in multiple centres in South Africa from April 2004 to December 2010. 1632 female patients diagnosed with breast cancer, with a median age of 51 years, were enrolled in the survey. Patients were treated on a docetaxel-based chemotherapy regimen. The objective of the study was to assess epidemiological data and survival data. The incidence of TNBC was 14%. The one-year survival rate for the total cohort was 84%. The one-year survival rate for patients with early stage and metastatic breast cancer was recorded as 94% and 65%, respectively. Patients with TNBC stage III (all ages) and stage IV (≤50 years) had statistically significant worse 1-year survival rate compared to N-TNBC patients of the same age and stages.Conclusion. The incidence of TNBC in South Africa which is 14% is comparable to global incidence. The 1-year survival data for certain subgroups supports the literature saying that TNBC carries a worse prognosis compared to N-TNBC. Women ≤50 years diagnosed with late stage TNBC carried the worst prognosis in this survey.


---

## Body

## 1. Introduction

Breast cancer is the leading cancer among South African women who have a 1 in 29 lifetime risk of developing breast cancer, with an age-standardized incidence rate of 30.6 per 100,000 population [1]. Triple-negative breast cancer (TNBC) is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) [2]. These cancers occur in approximately 12 to 17% of women with breast cancer and are associated with an unfavourable prognosis [3].Chemotherapy is the mainstay of advanced breast cancer treatment. Taxanes, together with anthracyclines, represent classes of drugs with very strong evidence of efficacy. Docetaxel, in particular, is an effective antineoplastic agent against both locally advanced and metastatic breast cancer and has shown increased survival rates in studies conducted in both early and advanced stage breast cancer patients irrespective of age, hormonal expression, or HER-2 status [4, 5].There is limited local epidemiological data on TNBC versus N-TNBC, especially with regard to the impact of age, stage, and treatment regimens on survival. In the Taxpas survey particular attention was paid to the TNBC subgroup of patients.


## 2. Methods

Taxpas was a prospective, non-randomized, multicenter, observational survey of breast cancer patients treated with a docetaxel-based chemotherapy regimen. The survey was conducted with the voluntary assistance of private sector oncologists from 46 centers in South Africa, who had made the independent decision to prescribe docetaxel to their patients. The physician, in accordance with their practice and ethical considerations, prescribed the dose and duration of treatment with guidance from the registered prescribing information for docetaxel. Patients participated in the survey on a voluntary basis and gave signed informed consent in accordance with full ethical approval by the local independent ethics board.


## 3. Statistical Analysis

Data from all the participating centers in South Africa were combined and treated as one dataset for the purposes of the analysis. The statistical analysis of the survey was of a descriptive nature where continuous variables were summarized by mean, median, and standard deviation and minimum and maximum values, and discrete variables were summarized by frequencies and percentages. The descriptive statistics were calculated for the total breast cancer cohort, subgroups (≤50 years and >50 years) to assess the influence of age and stage on overall survival, and TNBC and N-TNBC subtypes to more closely examine the effect of type of breast cancer on overall survival. A subset analysis of the one-year survival rate according to the stage of the disease was performed on the patients. Survival rates were analyzed using the Kaplan-Meier method. Refer to Figures1, 2, 3, 4, 5, 6, 7, and 8 for the Kaplan-Meier survival graphs according to stage of disease and age. P values were determined for the Kaplan-Meier curves using the logrank test. Hazard ratios for survival probability of TNBC versus N-TNBC, together with 95% confidence interval (CI), were calculated.Figure 1
Kaplan-Meier survival graph: stage I (age ≤ 50 years).Figure 2
Kaplan-Meier survival graph: stage I (age > 50 years).Figure 3
Kaplan-Meier survival graph: stage II (age ≤ 50 years).Figure 4
Kaplan-Meier survival graph: stage III (age > 50 years).Figure 5
Kaplan-Meier survival graph: stage III (age ≤ 50 years).Figure 6
Kaplan-Meier survival graph: stage III (age > 50 years).Figure 7
Kaplan-Meier survival graph: stage IV (age ≤ 50 years).Figure 8
Kaplan-Meier survival graph: stage IV (age > 50 years).All analyses were carried out on SAS, release 9.2, and run under Microsoft for a personal computer.


## 4. Results

### 4.1. Baseline Patient Characteristics

From April 30 2004, to December 4 2010, 1632 patients were enrolled with a median age of 51 years with ages ranging from 18 to 79 years. The staging at baseline showed that 1394 (85%) patients had early stage breast cancer, and 162 (10%) patients had metastatic disease. Please refer to Table1 to view patients enrolled in the study according to the stage of their disease. The staging at the 1-year followup showed that a total of 989 (61%) patients had early stage breast cancer and 560 (34%) patients had metastatic disease. The presence or absence of metastases was unknown for the remaining 83 (5%) patients at the 1-year followup visit.Table 1
Number of patients according to stage.
Overalln (%)
Early stage breast cancern (%)
Metastatic breast cancern (%)
Stage unknownn (%)
Total cohort at baseline
1632/1632 (100%)
1394/1632 (85%)
162/1632 (10%)
76/1632 (5%)
Total cohort at 1-year followup
1632/1632 (100%)
989/1632 (61%)
560/1632 (34%)
83/1632 (5%)
TNBC
232/1632 (14%)
149/232 (64%)
66/232 (28%)
17/232 (7%)
N-TNBC
1400/1632 (86%)
835/1400 (60%)
494/1400 (35%)
71/1400 (5%)
Age ≤50 years
757/1632 (46%)
520/757 (69%)
193/757 (25%)
44/757 (6%)
Age >50 years
875/1632 (53%)
464/875 (53%)
367/875 (42%)
44/875 (5%)


### 4.2. Disease Progression and Treatment Discontinuation

402 (24.6%) patients experienced disease progression during the 1-year followup period of which 94 (5.8%) patients experienced disease progression while being on treatment. 1316 (80.6%) patients completed their prescribed regimen of treatment. The reasons for treatment discontinuation were adverse events (6.4%), consent withdrawn (2.1%), disease progression (5.7%), death (1.9%), lost to followup (0.5%), and others (2.8%).


### 4.3. One-Year Survival

84% of the total cohort of patients (1369/1632) were alive at the one-year followup. 81% patients with TNBC (187/232) and 84% patients with N-TNBC (1182/1400) were alive at the 1-year followup visit. See Table2 for one-year survival of different subgroups. At stage IV of the disease, TNBC had a dramatic decline in survival with only 43% (patients ≤ 50 years) and 53% (patients > 50 years) alive at the 1-year followup (refer Table 3).Table 2
One-year survival rate.
Subgroup
Number of patients (%)
Total cohort (1632)
1369/1632 (84%)
Early stage breast cancer (989)
927/989 (94%)
Metastatic breast cancer (560)
364/560 (65%)
Stage unknown (85)
78/85 (92%)
Triple-negative breast cancer (232)
187/232 (81%)
Nontriple-negative breast cancer (1400)
1182/1400 (84%)Table 3
One-year survival according to stage and age.
TNBC ≤ 50 years
N-TNBC ≤ 50 years
TNBC > 50 years
N-TNBC > 50 years
Total
99/120 (83%)
571/637 (90%)
88/112 (79%)
611/763 (80%)
Stage I
15/17 (88%)
43/46 (93%)
8/9 (89%)
33/36 (92%)
Stage II
45/46 (98%)
210/218 (96%)
37/39 (95%)
211/225 (94%)
Stage III
20/22 (91%)
159/171 (93%)
13/16 (81%)
130/139 (94%)
Stage IV
12/28 (43%)
125/165 (76%)
20/38 (53%)
207/329 (63%)
Stage unknown
7/7 (100%)
34/37 (92%)
10/10 (100%)
30/34 (88%)


### 4.4. One-Year Survival in Patients with Metastatic Disease

In the TNBC subgroup 17% of the patients (32/187) who were alive at the 1-year followup visit were known to have had metastatic disease. In the N-TNBC group 1182 patients were alive at the 1-year followup visit with 28% of these patients (332/1182) being known to have had metastatic disease. It could be suggested that the poorer 1-year survival in TNBC versus N-TNBC could not be attributable to the amount of patients with metastatic disease, as a greater percentage of N-TNBC patients had metastatic disease.Hazard ratios for survival of TNBC versus N-TNBC, together with 95% confidence interval, are summarized in Table4. The data with asterisk in Table 4 indicate the stage and age combination where the survival curves differ significantly (by the logrank test, P<0.05), with corresponding hazard ratios indicating a statistically significant worse survival probability for patients with TNBC.Table 4
Statistical analyses based on survival curves: TNBC versus N-TNBC.
≤50 years
>50 years
LogrankP value
Hazard ratio (95% confidence interval)
LogrankP value
Hazard ratio
Stage I
P
=
0.440
0.352 (0.022–5.631)
P
=
0.428
Not calculable
Stage II
P = Not calculable
Not calculable
P
=
0.555
0.512 (0.053–4.926)
Stage III
P
=
0.017
*
0.133 (0.019–0.943)*
P
=
0.002
*
0.138 (0.031–0.619)*
Stage IV
P
=
0.012
*
0.444 (0.231–0.853)*
P
=
0.229
0.718 (0.417–1.235)


### 4.5. Safety Data

The main recorded adverse event was uncomplicated neutropenia, which occurred in 46.4% of patients. See Table5 for a list of adverse events and their frequencies.Table 5
Frequency of adverse events.
Adverse event
Number of patients (%)
Uncomplicated neutropenia
758 (46.4%)
Muscle cramps/spasms/myalgia
264 (16.2%)
Nail changes
239 (14.6%)
Anaemia
153 (9.4%)
Oral mucositis
33 (2.0%)
Anorexia
29 (1.8%)
Febrile neutropenia
23 (1.4%)
Neutropenic sepsis
22 (1.3%)
Asthenia
7 (0.4%)


## 4.1. Baseline Patient Characteristics

From April 30 2004, to December 4 2010, 1632 patients were enrolled with a median age of 51 years with ages ranging from 18 to 79 years. The staging at baseline showed that 1394 (85%) patients had early stage breast cancer, and 162 (10%) patients had metastatic disease. Please refer to Table1 to view patients enrolled in the study according to the stage of their disease. The staging at the 1-year followup showed that a total of 989 (61%) patients had early stage breast cancer and 560 (34%) patients had metastatic disease. The presence or absence of metastases was unknown for the remaining 83 (5%) patients at the 1-year followup visit.Table 1
Number of patients according to stage.
Overalln (%)
Early stage breast cancern (%)
Metastatic breast cancern (%)
Stage unknownn (%)
Total cohort at baseline
1632/1632 (100%)
1394/1632 (85%)
162/1632 (10%)
76/1632 (5%)
Total cohort at 1-year followup
1632/1632 (100%)
989/1632 (61%)
560/1632 (34%)
83/1632 (5%)
TNBC
232/1632 (14%)
149/232 (64%)
66/232 (28%)
17/232 (7%)
N-TNBC
1400/1632 (86%)
835/1400 (60%)
494/1400 (35%)
71/1400 (5%)
Age ≤50 years
757/1632 (46%)
520/757 (69%)
193/757 (25%)
44/757 (6%)
Age >50 years
875/1632 (53%)
464/875 (53%)
367/875 (42%)
44/875 (5%)


## 4.2. Disease Progression and Treatment Discontinuation

402 (24.6%) patients experienced disease progression during the 1-year followup period of which 94 (5.8%) patients experienced disease progression while being on treatment. 1316 (80.6%) patients completed their prescribed regimen of treatment. The reasons for treatment discontinuation were adverse events (6.4%), consent withdrawn (2.1%), disease progression (5.7%), death (1.9%), lost to followup (0.5%), and others (2.8%).


## 4.3. One-Year Survival

84% of the total cohort of patients (1369/1632) were alive at the one-year followup. 81% patients with TNBC (187/232) and 84% patients with N-TNBC (1182/1400) were alive at the 1-year followup visit. See Table2 for one-year survival of different subgroups. At stage IV of the disease, TNBC had a dramatic decline in survival with only 43% (patients ≤ 50 years) and 53% (patients > 50 years) alive at the 1-year followup (refer Table 3).Table 2
One-year survival rate.
Subgroup
Number of patients (%)
Total cohort (1632)
1369/1632 (84%)
Early stage breast cancer (989)
927/989 (94%)
Metastatic breast cancer (560)
364/560 (65%)
Stage unknown (85)
78/85 (92%)
Triple-negative breast cancer (232)
187/232 (81%)
Nontriple-negative breast cancer (1400)
1182/1400 (84%)Table 3
One-year survival according to stage and age.
TNBC ≤ 50 years
N-TNBC ≤ 50 years
TNBC > 50 years
N-TNBC > 50 years
Total
99/120 (83%)
571/637 (90%)
88/112 (79%)
611/763 (80%)
Stage I
15/17 (88%)
43/46 (93%)
8/9 (89%)
33/36 (92%)
Stage II
45/46 (98%)
210/218 (96%)
37/39 (95%)
211/225 (94%)
Stage III
20/22 (91%)
159/171 (93%)
13/16 (81%)
130/139 (94%)
Stage IV
12/28 (43%)
125/165 (76%)
20/38 (53%)
207/329 (63%)
Stage unknown
7/7 (100%)
34/37 (92%)
10/10 (100%)
30/34 (88%)


## 4.4. One-Year Survival in Patients with Metastatic Disease

In the TNBC subgroup 17% of the patients (32/187) who were alive at the 1-year followup visit were known to have had metastatic disease. In the N-TNBC group 1182 patients were alive at the 1-year followup visit with 28% of these patients (332/1182) being known to have had metastatic disease. It could be suggested that the poorer 1-year survival in TNBC versus N-TNBC could not be attributable to the amount of patients with metastatic disease, as a greater percentage of N-TNBC patients had metastatic disease.Hazard ratios for survival of TNBC versus N-TNBC, together with 95% confidence interval, are summarized in Table4. The data with asterisk in Table 4 indicate the stage and age combination where the survival curves differ significantly (by the logrank test, P<0.05), with corresponding hazard ratios indicating a statistically significant worse survival probability for patients with TNBC.Table 4
Statistical analyses based on survival curves: TNBC versus N-TNBC.
≤50 years
>50 years
LogrankP value
Hazard ratio (95% confidence interval)
LogrankP value
Hazard ratio
Stage I
P
=
0.440
0.352 (0.022–5.631)
P
=
0.428
Not calculable
Stage II
P = Not calculable
Not calculable
P
=
0.555
0.512 (0.053–4.926)
Stage III
P
=
0.017
*
0.133 (0.019–0.943)*
P
=
0.002
*
0.138 (0.031–0.619)*
Stage IV
P
=
0.012
*
0.444 (0.231–0.853)*
P
=
0.229
0.718 (0.417–1.235)


## 4.5. Safety Data

The main recorded adverse event was uncomplicated neutropenia, which occurred in 46.4% of patients. See Table5 for a list of adverse events and their frequencies.Table 5
Frequency of adverse events.
Adverse event
Number of patients (%)
Uncomplicated neutropenia
758 (46.4%)
Muscle cramps/spasms/myalgia
264 (16.2%)
Nail changes
239 (14.6%)
Anaemia
153 (9.4%)
Oral mucositis
33 (2.0%)
Anorexia
29 (1.8%)
Febrile neutropenia
23 (1.4%)
Neutropenic sepsis
22 (1.3%)
Asthenia
7 (0.4%)


## 5. Discussion

84% of the breast cancer patients were alive at the one-year followup. The latest age-standardized relative survival rate for breast cancer in England, during 2005–2009, shows that 95.8% of women are expected to survive their disease for at least one year [6]. The 1-year survival noted in the Taxpas survey was lower than the survival reflected in the cancer survival statistics in England. This could be due to the staging of the disease at the time of diagnosis. In the Taxpas survey patients with early stage breast cancer had a 1 year survival of 94% which is comparable to the England statistics. 14% of the survey’s patients had TNBC which is comparable to the global incidence [3]. The findings clearly showed that having TNBC rather than N-TNBC reduced the chances of survival by one year for all ages. This is in keeping with the current knowledge that TNBC carries a worse prognosis compared to N-TNBC, with no ability to derive benefit from molecularly targeted treatments such as endocrine therapy or trastuzumab, due to lack of appropriate targets for these drugs [3]. In our findings we see that survival rates were high and comparable between TNBC and N-TNBC in early disease (stages I and II), and only at stage III were marked differences seen between the two cancer types. The most dramatic decline in survival did not occur until stage IV where only 43% of TNBC patients were alive at one year. The Taxpas survey shows that this decline is most marked for patients ≤ 50 years. Younger women are more likely to have aggressive tumours and this may be affected by genetic factors [7].


## 6. Conclusion

The findings from this survey have contributed to our understanding of the epidemiology of TNBC in South Africa which was found to be comparable to global incidence. The one-year survival rate was found to be adversely affected by metastatic disease and TNBC. The survey indicated that women ≤ 50 years diagnosed with late stage TNBC carried the worst prognosis.



---

*Source: 308236-2013-12-11.xml*